T A D Q I Q O T L A R
jahon ilmiy – metodik jurnali
https://scientific-jl.com
64-son_2-to’plam_Iyun-2025
13
ISSN:3030-3613
CURRENT CONCEPTS IN CYSTITIS: EPIDEMIOLOGY, PATHOGENESIS,
AND CONTEMPORARY MANAGEMENT
Kamoljonova Go’zaloy Odiljon qizi
Abstract.
Cystitis—the inflammation of the urinary bladder—remains one of
the most common bacterial infections worldwide. Acute uncomplicated cystitis is
usually caused by Escherichia coli, whereas complicated and recurrent forms involve
a broader range of uropathogens and host factors. Recent guideline updates emphasise
rising antimicrobial resistance, the need for antibiotic-sparing strategies, and
individualised prevention. This three-page review synthesises the latest evidence on
epidemiology, pathophysiology, clinical presentation, diagnostic criteria, and
evidence-based treatment options, drawing on the 2024 European Association of
Urology (EAU) and 2024 Infectious Diseases Society of America (IDSA)
recommendations. Early recognition, appropriate antimicrobial stewardship, and
patient-centred preventive measures are critical to reducing morbidity and healthcare
costs associated with cystitis.
Key words:
cystitis, urinary tract infection, Escherichia coli, antimicrobial
resistance, nitrofurantoin, fosfomycin, recurrent UTI, bladder inflammation, diagnosis,
prevention
Introduction.
Cystitis accounts for >8 million outpatient visits annually and
affects up to 60 % of women at least once in their lifetime. Despite its benign
reputation, untreated or improperly managed infection can ascend to pyelonephritis,
provoke urosepsis, or become chronic. Evolving resistance patterns among
uropathogens challenge empirical therapy, necessitating regular guideline revision and
clinician awareness.
Pathophysiology & Microbiology
.
Most episodes are precipitated by ascending
coliform bacteria originating from the gastrointestinal tract; E. coli possesses adhesins
(P- and type-1 fimbriae) that facilitate urothelial attachment. Host factors—oestrogen
deficiency, sexual activity, urinary stasis, catheterisation—compromise natural
defences. Less common agents include Klebsiella spp., Staphylococcus saprophyticus,
and, in complicated cases, Enterococcus faecalis or multidrug-resistant (MDR) Gram-
negatives. Interstitial cystitis/bladder-pain syndrome involves non-infectious
inflammatory pathways, mast-cell activation, and urothelial glycosaminoglycan layer
defects.
A 2023 systematic review of 38 studies (n ≈ 1 million) estimated a global annual
incidence of 1.1–3.7 % for symptomatic urinary tract infection, with highest rates in
women aged 18-39 years. Pregnancy, diabetes mellitus, post-menopausal status, and
T A D Q I Q O T L A R
jahon ilmiy – metodik jurnali
https://scientific-jl.com
64-son_2-to’plam_Iyun-2025
14
ISSN:3030-3613
prior antibiotic exposure increase risk and recurrence. MDR uropathogens are
emerging in community-acquired infections, particularly in regions with high
fluoroquinolone and third-generation cephalosporin use.
Clinical Presentation
.
Typical features include dysuria, urinary urgency and
frequency, suprapubic discomfort, and cloudy or haematuric urine. Fever or flank pain
raises suspicion for upper-tract involvement. In the elderly or catheterised patients,
presentation may be atypical—new-onset delirium, urinary incontinence, or general
decline.
Uncomplicated cystitis (female) Nitrofurantoin 100 mg BID 5 days Fosfomycin
trometamol 3 g single dose; Trimethoprim-sulfamethoxazole 160/800 mg BID for 3
days if local resistance <20 %.
Pregnancy Nitrofurantoin (avoid at ≥38 weeks),
Amoxicillin-clavulanate 5-7 days Cephalexin 500 mg QID.
Lifestyle modification (fluid intake > 1.5 L/day, cranberries, D-mannose) shows
modest benefit. Vaginal oestrogen cream reduces recurrence in post-menopausal
women by restoring lactobacilli. Immunoprophylaxis (OM-89) demonstrates up to 34
% reduction in recurrences. Catheter management protocols—aseptic insertion, closed
drainage, early removal—are essential in healthcare settings.
Conclusion.
Cystitis continues to pose a substantial public-health burden,
complicated by escalating antimicrobial resistance. Adherence to contemporary
guidelines, culture-directed therapy, and preventive strategies can curtail recurrence
and preserve antibiotic efficacy. Ongoing surveillance and research into novel
therapeutics—phage therapy, microbiome modulation—are warranted to meet
emerging challenges.
References:
1.
European Association of Urology. EAU Guidelines on Urological Infections.
Limited Update 2024. Arnhem, The Netherlands: EAU Guidelines Office; 2024.
2.
Infectious Diseases Society of America. Guidance on the Treatment of
Antimicrobial-Resistant Gram-Negative Infections. 2024.
3.
Kot B., et al. (2024). Epidemiological trends and predictions of urinary tract
infections worldwide. Scientific Reports, 14, 89240.
4.
Nickel J.C., et al. (2023). International consultation on interstitial cystitis/bladder
pain syndrome. European Urology Focus, 9(6), 1414-1424.
5.
Gupta K., et al. (2019). Update on uncomplicated urinary tract infection in women.
Journal of Urology, 202(2), 282-289.
6.
Gajdács M., et al. (2023). Antimicrobial resistance in community-acquired
uropathogens: a global perspective. Antibiotics, 12(4), 511.
7.
Flores-Mir J.C., et al. (2022). Non-antibiotic prophylaxis for recurrent cystitis:
systematic review and meta-analysis. BMC Urology, 22, 17.
T A D Q I Q O T L A R
jahon ilmiy – metodik jurnali
https://scientific-jl.com
64-son_2-to’plam_Iyun-2025
15
ISSN:3030-3613
8.
Hooton T.M. (2021). Clinical practice. Uncomplicated urinary tract infection. New
England Journal of Medicine, 385, 2368-2376.
9.
Cai T., et al. (2020). Adherence to guidelines in the management of cystitis: a
multicentre Italian study. PLOS ONE, 15, e0244325.
10.
Wagenlehner F.M.E., et al. (2024). Emerging therapies for MDR urinary tract
infections. Clinical Microbiology Reviews, 37(2), e00123-23.
